Business Daily Media

Men's Weekly

.

Nasodine Research Points to Potential Role in CRS


Firebrick Pharma Limited (ASX: FRE) is pleased to announce the publication of new research into Nasodine® Nasal Spray identifying its potential in the management of chronic rhinosinusitis (CRS).

“To date, the development of Nasodine has focused on treatment of the common cold, which is generally caused by viruses,” said Firebrick Executive Chairman, Dr Peter Molloy. “This new research suggests it could also have a future role in bacterial CRS.”

CRS is an infection of the sinuses generally caused by strains of Staph. aureus. It is difficult to treat and becomes chronic because of the bacterium’s ability to shield itself from antibiotics and host immune responses by forming a protective ‘biofilm’.

The research evaluated for the first time the activity of Nasodine against S. aureus biofilms in vitro using a biofilm reactor model. Nasodine demonstrated time and concentration-dependent bacterial killing against intact biofilm with statistically significant reductions in viable bacteria with exposures as brief as 5 min. It consistently eradicated dispersed biofilm within 1 min.

The article concludes: “Nasodine is highly active against biofilms of S. aureus ATCC 6538 in vitro…Nasodine is an effective antibiofilm agent that holds promise for the management of sinonasal biofilms in CRS. Clinical trials are now required to determine whether this product offers clinical benefit for this condition.”

“Our clinical focus continues to be on Nasodine as a treatment for the common cold,” said Dr Molloy. “However, just as we have been exploring Nasodine’s potential in COVID-19, we may now want to consider its future development in CRS.”

Sponsored by Firebrick, the research was conducted at the University of Auckland and has now been published in the prestigious journal, The Laryngoscope1.

About CRS1

Chronic rhinosinusitis (CRS) is one of the most common chronic medical conditions worldwide, affecting all age groups. The estimated incidence of CRS is high: 12.3% in the USA, 10.9% in Europe and 13% in China.

Hale, S.J.M., Lux, C.A., Kim, R., Biswas, K., Tucker, S., Friedland, P., Mackenzie, B.W. and Douglas, R.G. (2023), In vitro Nasodine Can be an Effective Antibiofilm Agent for Biofilms that May Cause CRS. The Laryngoscope. https://doi.org/10.1002/lary.30558

Albu S. Chronic Rhinosinusitis-An Update on Epidemiology, Pathogenesis and Management. J Clin Med. 2020 Jul 18;9(7):2285. doi: 10.3390/jcm907228.

Minns Labor Government shutting down the Business Connect program

The NSW Opposition is concerned that the Labor government will shut down a support program that has assisted New South Wales businesses. In a media ...

Samsara Eco appoints Dr. Lars Kissau as General Manager for Asia

Australian biotech innovator Samsara Eco has announced the appointment of Dr Lars Kissau as its first General Manager of Asia. Based in Singapore...

From the first bounce to the final siren - small business lessons from the AFL Grand Final

The AFL Grand Final is one of the most anticipated days on the sporting calendar. This Saturday, the Geelong Cats and Brisbane Lions will battle i...

Australia’s top finance leaders recognised as CFO role expands

Amid surging regulatory demands and rapidly evolving industry, Australia’s most influential Chief Financial Officers will be honoured at the inaug...

Why outdated security leaves small businesses exposed to crime

Small and medium businesses in Australia are under increasing pressure to address security gaps that criminals readily exploit. An unlocked door, an...

Why it’s time telcos rethink location and put customer experience first

Maurice Zicman, Vice President - CX Strategy at TP in Australia unpacks why the telco industry must rethink old assumptions and focus on digital-f...